Scott Rottinghaus
Chief Tech/Sci/R&D Officer bei ENANTA PHARMACEUTICALS, INC.
Vermögen: 493 891 $ am 31.03.2024
Profil
Scott T.
Rottinghaus is currently the Chief Medical Officer & Senior Vice President at Enanta Pharmaceuticals, Inc. Previously, he worked as the Vice President & Head-Clinical Development at Alexion Pharmaceuticals, Inc. He received his doctorate from Mayo Medical School, his graduate degree from the University of Cambridge, and his undergraduate degree from Kansas State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 12.02.2024 | 28 287 ( 0,13% ) | 493 891 $ | 31.03.2024 |
Aktive Positionen von Scott Rottinghaus
| Unternehmen | Position | Beginn |
|---|---|---|
| ENANTA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 08.08.2022 |
Ehemalige bekannte Positionen von Scott Rottinghaus
| Unternehmen | Position | Ende |
|---|---|---|
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Scott Rottinghaus
| University of Cambridge | Graduate Degree |
| Kansas State University | Undergraduate Degree |
| Mayo Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| ENANTA PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
